Cost-Effectiveness of perioperative Vaginally Administered estrogen in postmenopausal women undergoing prolapse surgery (EVA trial): study protocol for a multicenter double-blind randomized placebo-controlled trial

E.V. Vodegel*, S.E. Zwolsman, A. Vollebregt, R.G. Duijnhoven, J.E. Bosmans, L. Speksnijder, E.J. Roos, W. Spaans, F. Gerards, A. Adriaanse, F. Vernooij, A.L. Milani, M. Sikkema, M. Weemhoff, M. Mous, A. Damoiseaux, H. van Dongen, M. v d Ploeg, J. Veen, G. van de PolB. Broekman, P. Steures, F. Tjin-Asjoe, J. van der Stege, R. Mouw, C.H. van der Vaart, J.P.W.R. Roovers

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Article number439
Number of pages10
JournalBMC Women's Health
Volume21
Issue number1
DOIs
Publication statusPublished - 31 Dec 2021

Keywords

  • Pelvic organ prolapse
  • Vaginal estrogen therapy
  • Postmenopausal
  • Wound healing
  • Pelvic reconstructive surgery
  • Recurrence
  • Cost-effectiveness
  • PELVIC ORGAN PROLAPSE
  • LOCAL ESTROGEN
  • LIFETIME RISK
  • ESTRADIOL
  • QUESTIONNAIRE
  • VALIDATION
  • RECURRENCE
  • OUTCOMES
  • SUPPORT
  • ATROPHY

Cite this